Text Version
Entrez PubMed Overview Help | FAQ Tutorial New/Noteworthy E-Utilities
PubMed Services Journals Database MeSH Database Single Citation Matcher Batch Citation Matcher Clinical Queries LinkOut Cubby
Related Resources Order Documents NLM
Gateway TOXNET Consumer
Health Clinical Alerts ClinicalTrials.gov PubMed
Central
Privacy Policy
|
|
-
Adverse reactions to five new
antidepressants.
Hayes PE, Kristoff
CA.
Postmarketing adverse drug reaction reports for
amoxapine, maprotiline hydrochloride, and trazodone hydrochloride and
premarketing adverse drug reaction data for bupropion hydrochloride and
nomifensine maleate are reviewed, and the role of the new agents in the
management of depressive illness is discussed. Nomifensine was withdrawn
from markets worldwide because of reports of serious hypersensitivity
reactions, especially hemolytic anemia, and marketing of bupropion in
the United States was delayed after seizures occurred in bulimic
patients in clinical trials. Amoxapine and maprotiline, when taken in
overdose attempts, are more toxic and cause more serious central nervous
system reactions than the standard tricyclics. Acute renal failure and
an increased mortality rate are associated with amoxapine overdose.
Amoxapine causes several acute and chronic untoward neurologic and
endocrine reactions not commonly associated with the standard
tricyclics. For maprotiline and bupropion, maximum doses have been
established because of dose-related seizures. Trazodone has minimal
effect on cardiac conduction; its main cardiovascular effects are
hypotension, orthostasis, and dizziness. The trazodone package insert
has been revised to warn of priapism; patients with prolonged or
inappropriate penile erections are instructed to discontinue the drug
and notify the physician. Serious cardiovascular and neurologic
toxicities are rare with trazodone overdose. Of the newly marketed
antidepressants, only trazodone offers some advantages over the
tricyclic and tetracyclic agents in the areas of side effects and
toxicities. The number and type of patients exposed to a new drug during
clinical trials is too small for detection of rare but potentially
serious adverse effects.
Publication Types:
PMID: 3087684 [PubMed - indexed for MEDLINE]
|